市場調査レポート
商品コード
1433051

医薬品・バイオテクノロジーにおけるオプションおよび評価取引 (2016~2024年)

Option and Evaluation Deals in Pharmaceuticals and Biotechnology 2016-2024

出版日: | 発行: Current Partnering | ページ情報: 英文 700+ Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.49円
医薬品・バイオテクノロジーにおけるオプションおよび評価取引 (2016~2024年)
出版日: 2024年03月01日
発行: Current Partnering
ページ情報: 英文 700+ Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の医薬品・バイオテクノロジーにおけるオプションおよび評価取引の締結情況について分析し、全体的な取引件数・取引額の推移や予測 (2016~2024年)、近年の代表的取引の事例、主要企業による取引締結の動き、技術別・治療領域別の契約条件の傾向、といった情報を取りまとめてお届けいたします。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 オプションおよび評価取引 の動向

  • イントロダクション
  • オプションおよび評価取引 の定義
  • オプションおよび評価取引 の動向 (2016年以降)
    • オプションおよび評価取引 の動向:年別 (2016~2024年)
    • オプションおよび評価取引 の動向:開発段階別 (2016~2024年)
    • オプションおよび評価取引 の動向:産業分野別 (2016~2024年)
    • オプションおよび評価取引 の動向:治療領域別 (2016~2024年)
    • オプションおよび評価取引 の動向:技術の種類別 (2016~2024年)
    • オプションおよび評価取引 の動向:最も活発な企業の場合 (2016~2024年)
  • オプションおよび評価の提携取引を締結する理由
  • オプションおよび評価取引 の将来性

第3章 オプションおよび評価取引の構造:概要

  • イントロダクション
  • オプションおよび評価契約の構造

第4章 オプションおよび評価の主要な取引

  • イントロダクション
  • 上位のオプションおよび評価の取引 (金額ベース)

第5章 オプションおよび評価取引 :最も活発な取引締結企業25社

  • イントロダクション
  • オプションおよび評価取引 :最も活発な取引締結企業25社

第6章 オプションおよび評価取引 :契約の内訳

  • イントロダクション
  • オプションおよび評価契約 (2016~2024年)
  • 取引内訳
  • 取引内訳:オプションおよび評価の取引締結、企業名別 (A~Z)
  • 取引内訳:オプションおよび評価の取引締結、治療領域別
  • 取引内訳:オプションおよび評価の取引締結、技術の種類別

Wildwood Venturesについて

目次
Product Code: CP2059

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter option and evaluation deals.

Fully revised and updated, the report provides details of option and evaluation deals from 2016 to 2024.

The report provides access to option and evaluation deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of option and evaluation deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in option and evaluation as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of option and evaluation deals.

Chapter 4 provides a review of the leading option and evaluation deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active option and evaluation dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of option and evaluation deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the option and evaluation deal.

The deal directory includes a comprehensive listing of all option and evaluation deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in option and evaluation dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about option and evaluation alliances.

Key benefits

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse option and evaluation deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

  • Option and Evaluation Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the option and evaluation trends and structure of deals entered into by leading biopharma companies worldwide.

Option and Evaluation Deals in Pharmaceuticals and Biotechnology includes:

  • Trends in option and evaluation dealmaking in the biopharma industry
  • Overview of option and evaluation deal structure
  • Directory of option and evaluation deal records covering pharmaceutical and biotechnology
  • The leading option and evaluation deals by value
  • Most active option and evaluation dealmakers
  • The leading option and evaluation partnering resources

In Option and Evaluation Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type
  • Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
  • Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for option and evaluation deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the rights granted or optioned?
  • What rights are granted by the agreement?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are intellectual property rights handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in option and evaluation dealmaking

  • 2.1. Introduction
  • 2.2. Definition of option and evaluation deal
  • 2.3. Trends in option and evaluation deals since 2016
    • 2.3.1. Option and evaluation dealmaking by year, 2016-2024
    • 2.3.2. Option and evaluation dealmaking by phase of development, 2016-2024
    • 2.3.3. Option and evaluation dealmaking by industry sector, 2016-2024
    • 2.3.4. Option and evaluation dealmaking by therapy area, 2016-2024
    • 2.3.5. Option and evaluation dealmaking by technology type, 2016-2024
    • 2.3.6. Option and evaluation dealmaking by most active company, 2016-2024
  • 2.4. Reasons for entering into option and evaluation partnering deals
  • 2.5. The future of option and evaluation deals

Chapter 3 - Overview of option and evaluation deal structure

  • 3.1. Introduction
  • 3.2. Option and evaluation agreement structure

Chapter 4 - Leading option and evaluation deals

  • 4.1. Introduction
  • 4.2. Top option and evaluation deals by value

Chapter 5 - Top 25 most active option and evaluation dealmakers

  • 5.1. Introduction
  • 5.2. Top 25 most active option and evaluation dealmakers

Chapter 6 - option and evaluation deals including contracts directory

  • 6.1. Introduction
  • 6.2. Option and evaluation deals with contracts 2016-2024
  • Deal directory
  • Deal directory - option and evaluation dealmaking by companies A-Z
  • Deal directory - option and evaluation dealmaking by therapy area
  • Deal directory - option and evaluation dealmaking by technology type

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

TABLE OF FIGURES

  • Figure 1: Definition of option and evaluation
  • Figure 2: Trends in option and evaluation deal announcements, 2016-2024
  • Figure 3: Option and evaluation deals signed at each phase of development, 2016-2024
  • Figure 4: Option and evaluation deals by industry sector, 2016-2024
  • Figure 5: Option and evaluation deals by therapy area, 2016-2024
  • Figure 6: Option and evaluation deals by technology type, 2016-2024
  • Figure 7: Top 25 most active option and evaluation dealmakers, 2016-2024
  • Figure 8: Top option and evaluation deals by value, 2016-2024
  • Figure 9: Most active option and evaluation dealmakers, 2016-2024